Sunday share tips: Shaftesbury, Sensyne Health, Standard Chartered

(Sharecast News) - Newspaper share tips from the Sunday Times on Shaftesbury, the Mail on Sunday on Sensyne Health and the Sunday Telegraph on Standard Chartered.Shaftesbury, the West End landlord, was tipped as a 'buy' by the Sunday Times' Inside the City column. Last week's news that a consortium is looking at buying retail property group Intu is a sign of deal-making returning to the sector. "Shaftesbury is a more attractive proposition," the column said, having generated consistent growth in net asset value and rental income over many years. Not helped by a recent update, shares in Shaftesbury have dropped almost 15% since the start of the year to below 900p for the first time since early 2017 compared to its most recent NAV per share of 983p.Many high street landlords have been hit by beleaguered retailers looking to cut their lease obligations via a controversial scheme called company voluntary arrangements, but Shaftesbury is thought not to have had a single one. Moreover, the FTSE 250-listed group's Covent Garden location makes it less dependent on UK consumers, with tourist money helping keeping footfall up at its clients' outlets.Shaftesbury shares ended last week at the exact same share price that property billionaire Sammy Tak Lee made an offer to buy a 9.3% stake in 2015. This month he has upped his stake to 26.2% from 25%, not far from the 30% level at which a takeover offer is mandatory. However, Norway's sovereign wealth fund, Norges Bank, is has a sizeable 21% piece of the pie.The tip for Midas in the Mail on Sunday was to "buy" Sensyne Health, a pioneer in clinical artificial intelligence that uses the vast amounts of anonymous data from the NHS to diagnose patterns in cancer, heart disease and lung disease, as well as conditions such as Alzheimer's and diabetes. Sensyne, founded by Powderjet entrepreneur Paul Drayson, acts as a middleman between the NHS and drug developers. Revenues are forecast at just £100,000 this year and are forecast to grow to above £12m by 2021, with losses expected for the next few years.Listed on AIM since August, the company has deals with three NHS trusts and aims to add three more before the end of 2020. Sensyne, which pays trusts in shares and and a share of the payments it gets from drug companies, analyses the data for clues about how diseases arise and develop. It has already made some major breakthroughs, including developing apps used on tablets and smartphones to monitor heart conditions, lung disease and diabetes among pregnant women.Its SEND app analyses patients at risk of cardiac arrest while they are in hospital and has apparently cut heart attacks on the ward by 20%. Another app is used at home by lung disease sufferers as a form of triage. These apps to do not currently generate revenues but are just used to generate more data, though overseas use could generate revenue.Standard Chartered was under the microscope of Questor in the Sunday Telegraph. The business may look "safe as houses" - but "safety doesn't mean growth" and the advice is to "avoid".Please note: Digital Look/Sharecast provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look/Sharecast cannot take any responsibility for information provided by third parties. This is for your general information only and not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.